Charting the sequence-activity landscape of peptide inhibitors of translation termination
Apidaecin (Api), an unmodified 18-amino-acid-long proline-rich antibacterial peptide produced by bees, has been recently described as a specific inhibitor of translation termination. It invades the nascent peptide exit tunnel of the postrelease ribosome and traps the release factors preventing their recycling. Api binds in the exit tunnel in an extended conformation that matches the placement of a nascent polypeptide and establishes multiple contacts with ribosomal RNA (rRNA) and ribosomal proteins. Which of these interactions are critical for Api's activity is unknown. We addressed this problem by analyzing the activity of all possible single-amino-acid substitutions of the Api variants synthesized in the bacterial cell. By conditionally expressing the engineered api gene, we generated Api directly in the bacterial cytosol, thereby bypassing the need for importing the peptide from the medium. The endogenously expressed Api, as well as its N-terminally truncated mutants, retained the antibacterial properties and the mechanism of action of the native peptide. Taking advantage of the Api expression system and next-generation sequencing, we mapped in one experiment all the single-amino-acid substitutions that preserve or alleviate the on-target activity of the Api mutants. Analysis of the inactivating mutations made it possible to define the pharmacophore of Api involved in critical interactions with the ribosome, transfer RNA (tRNA), and release factors. We also identified the Api segment that tolerates a variety of amino acid substitutions; alterations in this segment could be used to improve the pharmacological properties of the antibacterial peptide.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:118 |
|---|---|
| Enthalten in: |
Proceedings of the National Academy of Sciences of the United States of America - 118(2021), 10 vom: 09. März |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Baliga, Chetana [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 16.08.2021 Date Revised 06.09.2021 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1073/pnas.2026465118 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM322316650 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM322316650 | ||
| 003 | DE-627 | ||
| 005 | 20231225181800.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1073/pnas.2026465118 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1074.xml |
| 035 | |a (DE-627)NLM322316650 | ||
| 035 | |a (NLM)33674389 | ||
| 035 | |a (PII)e2026465118 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Baliga, Chetana |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Charting the sequence-activity landscape of peptide inhibitors of translation termination |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 16.08.2021 | ||
| 500 | |a Date Revised 06.09.2021 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Apidaecin (Api), an unmodified 18-amino-acid-long proline-rich antibacterial peptide produced by bees, has been recently described as a specific inhibitor of translation termination. It invades the nascent peptide exit tunnel of the postrelease ribosome and traps the release factors preventing their recycling. Api binds in the exit tunnel in an extended conformation that matches the placement of a nascent polypeptide and establishes multiple contacts with ribosomal RNA (rRNA) and ribosomal proteins. Which of these interactions are critical for Api's activity is unknown. We addressed this problem by analyzing the activity of all possible single-amino-acid substitutions of the Api variants synthesized in the bacterial cell. By conditionally expressing the engineered api gene, we generated Api directly in the bacterial cytosol, thereby bypassing the need for importing the peptide from the medium. The endogenously expressed Api, as well as its N-terminally truncated mutants, retained the antibacterial properties and the mechanism of action of the native peptide. Taking advantage of the Api expression system and next-generation sequencing, we mapped in one experiment all the single-amino-acid substitutions that preserve or alleviate the on-target activity of the Api mutants. Analysis of the inactivating mutations made it possible to define the pharmacophore of Api involved in critical interactions with the ribosome, transfer RNA (tRNA), and release factors. We also identified the Api segment that tolerates a variety of amino acid substitutions; alterations in this segment could be used to improve the pharmacological properties of the antibacterial peptide | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, U.S. Gov't, Non-P.H.S. | |
| 650 | 4 | |a antibiotic | |
| 650 | 4 | |a apidaecin | |
| 650 | 4 | |a nascent peptide exit tunnel | |
| 650 | 4 | |a ribosome | |
| 650 | 4 | |a translation termination | |
| 650 | 7 | |a Antimicrobial Cationic Peptides |2 NLM | |
| 650 | 7 | |a Protein Synthesis Inhibitors |2 NLM | |
| 650 | 7 | |a RNA, Bacterial |2 NLM | |
| 650 | 7 | |a RNA, Ribosomal |2 NLM | |
| 650 | 7 | |a apidaecin |2 NLM | |
| 650 | 7 | |a 123997-21-7 |2 NLM | |
| 700 | 1 | |a Brown, Tyler J |e verfasserin |4 aut | |
| 700 | 1 | |a Florin, Tanja |e verfasserin |4 aut | |
| 700 | 1 | |a Colon, Sarah |e verfasserin |4 aut | |
| 700 | 1 | |a Shah, Vallari |e verfasserin |4 aut | |
| 700 | 1 | |a Skowron, Kornelia J |e verfasserin |4 aut | |
| 700 | 1 | |a Kefi, Amira |e verfasserin |4 aut | |
| 700 | 1 | |a Szal, Teresa |e verfasserin |4 aut | |
| 700 | 1 | |a Klepacki, Dorota |e verfasserin |4 aut | |
| 700 | 1 | |a Moore, Terry W |e verfasserin |4 aut | |
| 700 | 1 | |a Vázquez-Laslop, Nora |e verfasserin |4 aut | |
| 700 | 1 | |a Mankin, Alexander S |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Proceedings of the National Academy of Sciences of the United States of America |d 1915 |g 118(2021), 10 vom: 09. März |w (DE-627)NLM000008982 |x 1091-6490 |7 nnns |
| 773 | 1 | 8 | |g volume:118 |g year:2021 |g number:10 |g day:09 |g month:03 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1073/pnas.2026465118 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 118 |j 2021 |e 10 |b 09 |c 03 | ||